Commercial CAR-T in China: Pricing Breakdown & Sources
This page explains how commercial CAR-T drug pricing in China is established from official NMPA-approved list prices, how standard patient discounts apply to international patients, what hospital bills beyond the cell product typically look like at public wards, public international departments, and private international hospitals, and how to identify fraudulent low-cost offers.
1. The Official ¥1,150,000 List Price & ¥300,000 Reduction
In China, commercially approved autologous BCMA CAR-T therapies—福可苏® (eque-cel, NMPA approval 国药准字S20230006) and 赛恺泽® (zevor-cel, NMPA approval 国药准字S20240007)—are registered on official provincial public pharmaceutical procurement platforms with a regulated nationwide retail list price of ¥1,150,000 RMB for cell manufacturing and batch release. This is a regulated drug list price, not an all-inclusive hospital package.
Commercial manufacturers provide an official ¥300,000 RMB standard patient assistance reduction program. International patients are equally eligible for this reduction across all authorized Chinese hospitals (both public tertiary centers and private international hospitals), bringing the net cell product cost to approximately ¥850,000 RMB before hospital admission, tests, and procedural care.
Interactive All-In Cost Estimator
Calculate your complete estimated expenditure (Net Drug + Hospital Inpatient & Work-Up) in RMB or your home currency.
1. Net Drug Cost (After ¥300k Discount)
~¥850,000 CNY
Regulated NMPA standard price
2. Est. Hospital Inpatient & Work-Up
~¥150,000 – ¥350,000
Public IMC setting
~¥1,000,000 – ¥1,200,000
Official hospital billing total in RMB (excl. airfare & lodging)
Pricing Integrity & Scam Prevention
To protect international patients from fraudulent broker packages or unregulated investigational products, keep these two commercial benchmarks in mind:
•Drug Cost Rule: Licensed NMPA commercial cell drug alone costs ~¥850,000 RMB (~$120,000 USD). Any offer quoting drug costs below $120,000 USD requires extreme caution.
•All-Inclusive Total Rule: Genuine private international care (drug + inpatient hospital stay) typically totals $160,000–$215,000 USD. Any broker offering an “all-inclusive private package” below $160,000 USD is a high-risk warning sign.
💡 Free verification: You can send written third-party quotes or pro-forma invoices to CMDN for independent verification before making any deposits.
2. Hospital Costs Beyond the Cell Product — Three Tiers
The cell product is billed separately from the hospital. A typical commercial myeloma CAR-T episode still includes work-up (PET-CT, marrow, echo, infection panel), apheresis, Flu/Cy lymphodepletion, 7–14 days in a HEPA isolation room, daily labs, supportive medicines, and optional bridging or ICU days. The 8–10 week stay in China is mostly outpatient lodging during manufacturing and the 30-day safety window — that lodging is not in the hospital bill.
No Chinese hospital publishes a binding, itemized CAR-T non-drug package online for international patients. The ranges below are order-of-magnitude estimates built from posted municipal tariffs × a typical isolation stay, plus work-up and supportive care. They are not quotes. Ask the treating hospital for a written estimate after record review.
Hospital Type | Hospital Bill Inpatient care excl. drug | Estimated Total (RMB) Cell product + hospital bill | Estimated Total (USD) Live rate (~6.75 CNY/USD) | Cost Drivers Tariff & service factors |
|---|---|---|---|---|
Public hospital (general ward) Lowest daily tariffs | ¥80,000–220,000 | ~¥930,000– 1,070,000 | ~$137,715– $158,446 USD | Municipal bed & nursing tariffs. Ordinary isolation rooms. Mandarin-only ward rounds. |
Public hospital (IMC department) Moderate premium | ¥150,000–350,000 | ~¥1,000,000– 1,200,000 | ~$148,080– $177,696 USD | Same faculty & public test pricing; upgraded private rooms with special-needs (特需) tariffs. |
Private international hospital Full international service | ¥250,000–600,000 | ~¥1,100,000– 1,450,000 | ~$162,888– $214,716 USD | Single-room isolation, direct English clinical care, and visa (S2) assistance included. |
How the public-ward range was built
Posted public tariffs for ordinary/laminar beds are low: Shanghai Xinhua lists laminar-clean beds at ¥90/day and ordinary single rooms from ¥398/day; three-bed wards are ¥68/day. Isolation plus Flu/Cy, PET-CT, marrow, echo, labs, and supportive medicines still add up. Public compilations of China CAR-T episodes typically put hospitalization around ¥20,000–50,000, tests ¥10,000–30,000, lymphodepletion ¥10,000–30,000, and supportive care ¥10,000–50,000. Adding those blocks, and allowing for one tocilizumab course or a few extra isolation days, gives about ¥80,000–220,000 before catastrophic ICU. For comparison, U.S. peri-infusion hospital care excluding the cell product is about $23,000 (Jagannath et al., 2023).
How the international-department range was built
Ruijin Hospital’s published international-department rules are the cleanest official template: tests, labs, and drugs stay at ordinary public prices; only bed, inpatient physician visit, and nursing use special-needs prices. Shanghai Children’s Hospital’s June 2026 posting lists special-needs single rooms at ¥1,200/day, internal-medicine visit ¥1,000/day, and level-1 nursing ¥700/day — about ¥2,900/day for those three lines alone. Sun Yat-sen First Affiliated posts special-needs beds at ¥1,200–2,800/day. A 2015 Shanghai health-policy paper, citing the 2012 municipal special-needs rule (沪卫规财〔2012〕022号), recorded special-needs beds up to ¥6,000/day and a 2013 mean special-needs bed-day cost of ¥4,662. Twelve to sixteen isolation/monitoring days at ¥2,900–5,000, plus public-rate work-up and chemo, lands near ¥150,000–350,000.
How the private-international range was built
Licensed private international hospitals in China typically do not publish fixed, itemized all-inclusive CAR-T packages online. Public clinical explainers split CAR-T bills into two distinct components: the regulated commercial cell drug and non-drug hospital care. Private single-room oncology isolation stays in Tier-1 cities incur higher daily room, nursing, and private test tariffs. Independent industry compilations place a complete China commercial CAR-T episode at approximately ¥1.10–1.65 million RMB. Subtracting the ~¥850,000 discounted drug leaves an indicative hospital-side non-drug band of about ¥250,000–600,000 for an uncomplicated to moderately complicated case.
3. Inpatient Care, Bridging, and ICU Monitoring
Severe cytokine release syndrome (Grade ≥3 CRS) occurs in only ~1.0% to ~6.9% of myeloma patients treated with China’s approved commercial products. Among the minority of patients who require temporary intensive care escalation, published clinical cohorts report a median ICU stay of 4–5 days (Constantinescu et al., 2023):
Grade 1–2 Mild CRS (Standard Ward Care)
~90% of treated patients
Managed on the routine hematology ward with antipyretics, supportive fluids, and IL-6 receptor antagonists (such as tocilizumab) as clinically indicated.
ICU Escalation (Severe CRS / Neurotoxicity)
Occurs in a small minority; median 4–5 ICU days
In China, all CAR-T administering hematology centers must maintain an on-site ICU. Intensive care stays are billed at standard hospital critical care daily tariffs based on actual clinical interventions.
4. How to read a quote against the commercial floor
A third-party “all-in CAR-T in China” price should be checked against the drug floor and the hospital tier. The numbers below are planning ranges, not a quote:
1. The ~$120k–$126k Drug-Only Floor
The net NMPA commercial cell product alone is ~¥850,000 RMB (~$120,000–$126,000 USD) before any hospital bills. Any broker offer claiming an all-inclusive trip under this threshold sits below pure cell manufacturing cost and cannot cover licensed commercial cell manufacturing.
Rule: Below ~$120k rarely covers licensed commercial CAR-T
2. Public General Ward (~$135k–$158k)
Legitimate public general ward episodes land around ~$135,000–$158,000 USD total. However, public hospitals bill directly in RMB with no intermediary packages; ward rounds are in Mandarin and foreign families must arrange their own independent daily logistics.
Rule: Real public care = Direct RMB hospital billing
3. Private-hospital packages under $150k
Legitimate private international hospitals with English care cost ~$160,000–$215,000 USD total. Third-party brokers advertising “full private concierge packages with lodging and translation for under $150,000 USD” often will not match a licensed private-hospital invoice, or describe a pathway that is not commercially released.
Rule: Private packages under $150k should be verified
5. Published Academic & Regulatory Sources
All data points on this page are cross-referenced with peer-reviewed publications and official regulatory databases:
NMPA Regulated Drug Approval: Equecabtagene Autoleucel (福可苏®)
National Medical Products Administration (NMPA) Approval No. 国药准字S20230006.
Official provincial public procurement centralized listing price: ¥1,150,000 RMB.
NMPA Regulated Drug Approval: Zevorcabtagene Autoleucel (赛恺泽®)
National Medical Products Administration (NMPA) Approval No. 国药准字S20240007.
Official provincial public procurement centralized listing price: ¥1,150,000 RMB.
FUMANBA-1 Registrational Trial (Eque-cel)
Li et al., JAMA Oncology 2024;10(12):1678–1686.
n=103; Any-grade CRS: 93.2%, Grade ≥3 CRS: 1.0%, Grade ≥3 ICANS: 0.0%.
LUMMICAR-1 Phase 2 Registrational Trial (Zevor-cel)
Exp Hematol Oncol 2025;14(1):22.
n=102; Any-grade CRS: 90.2%, Grade ≥3 CRS: 6.9% (all resolved within median 4 days), Grade ≥3 ICANS: 0.0%.
U.S. CAR-T Peri-Infusion Hospitalization Costs
Jagannath et al., Transplant Cell Ther 2023;29(5):317.e1-317.e8.
Median non-drug peri-infusion hospital cost was ~$23,154 for myeloma cohorts.
ICU Stay Duration Following CAR-T Cell Therapy
Constantinescu et al., J Clin Med 2023;12(9):3259.
Established median ICU length of stay at 4–5 days among patients requiring intensive care.
Shanghai Xinhua Hospital public tariff posting
Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, medical-service price list.
Laminar-clean bed ¥90/day; ordinary single rooms ¥398–¥3,500/day; three-bed ward ¥68/day.
Shanghai Children’s Hospital special-needs tariff posting
Shanghai Children’s Hospital price notice, 30 June 2026.
Special-needs single room ¥1,200/day; internal-medicine visit ¥1,000/day; level-1 nursing ¥700/day.
Shanghai special-needs pricing rule and 2013 bed-day study
Hu et al., Chinese Journal of Health Policy, 2015;8(3). Cites 沪卫规财〔2012〕022号.
Only bed, inpatient visit, nursing, and outpatient visit may use market special-needs prices; other items stay on basic medical tariffs. 2013 mean special-needs bed-day cost ¥4,662; posted special-needs beds up to ¥6,000/day.
Ruijin Hospital International Medical Center fee rules
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, international-department charging standard.
International department operates outside basic municipal medical insurance. Labs, tests, and drugs follow ordinary public prices; only bed, visit, and nursing use special-needs prices.
Private International Center CAR-T Pricing Architecture
Public clinical disclosure by licensed private international tertiary center.
Clarifies that commercial CAR-T is billed in two separate blocks (regulated cell product vs. inpatient hospital care) rather than fixed all-inclusive package pricing.
CMS Part B Average Sales Price (ASP) Drug Files
U.S. Centers for Medicare & Medicaid Services (CMS), Mid-2026 Payment Limits.
HCPCS Q2056 (Cilta-cel ~$588k) and Q2055 (Ide-cel ~$568k).
Institutional Notice: China Myeloma Digital Network (CMDN) is an independent non-profit patient advocacy organization. CMDN does not hold patient funds or set medical prices. All medical evaluations, treatment protocols, and formal invoices are issued directly by licensed treating hospitals.